Conclusions Short-term fish oil supplementation is associated with increasing the insulin sensitivity among those people with metabolic disorders
Background Fish oil supplementation has been shown to be associated with a lower risk of metabolic syndrome and benefit a wide range of chronic diseases , such as cardiovascular disease , type 2 diabetes and several types of cancers .
However , the evidence of fish oil supplementation on glucose metabolism and insulin sensitivity is still controversial .
This meta- analysis summarized the exist evidence of the relationship between fish oil supplementation and insulin sensitivity and aim ed to evaluate whether fish oil supplementation could improve insulin sensitivity .
Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.
Hepatic accumulation of lipid substrates perturbs apolipoproteinB-100 ( apoB ) metabolism in insulin-resistant , obese subjects and may account for increased risk of cardiovascular disease . In a placebo-controlled trial , we examined the independent and combined effects of decreasing cholesterol synthesis with atorvastatin ( 40 mg/day ) and triglyceride synthesis with fish oils ( 4 g/day ) on apoB kinetics . The subjects were 48 viscerally obese , insulin-resistant men with dyslipidemia who were studied in a fasted state . We found that atorvastatin significantly decreased plasma apoB-containing lipoproteins ( P < 0.001 , main effect ) through increases in the fractional catabolic rate ( FCR ) of VLDL- , IDL- , and LDL-apoB ( P < 0.01 ) . Fish oils significantly decreased plasma levels of triglycerides and VLDL-apoB ( P < 0.001 ) , decreased the VLDL-apoB secretion rate ( P < 0.01 ) , but increased the conversion of VLDL to LDL ( P < 0.001 ) . Compared with placebo , combined treatment with atorvastatin and fish oils decreased VLDL-apoB secretion ( P < 0.03 ) and increased the FCR of apoB in each lipoprotein fraction ( P < 0.03 ) and the percent conversion of VLDL to LDL ( P < 0.05 ) . None of the treatments altered insulin resistance . In conclusion , in visceral obesity , atorvastatin increased hepatic clearance of all apoB-containing lipoproteins , whereas fish oils decreased hepatic secretion of VLDL-apoB. The differential effects of atorvastatin and fish oils on apoB kinetics support their combined use in correcting defective apoB metabolism in obese , insulin-resistant subjects
Conclusions Short-term fish oil supplementation is associated with increasing the insulin sensitivity among those people with metabolic disorders
Background Fish oil supplementation has been shown to be associated with a lower risk of metabolic syndrome and benefit a wide range of chronic diseases , such as cardiovascular disease , type 2 diabetes and several types of cancers .
However , the evidence of fish oil supplementation on glucose metabolism and insulin sensitivity is still controversial .
This meta- analysis summarized the exist evidence of the relationship between fish oil supplementation and insulin sensitivity and aim ed to evaluate whether fish oil supplementation could improve insulin sensitivity .